Key Highlights

• Regencell fell nearly 23% to close at $8.56 on June 24 with no company-specific catalyst identified.

• The company has a tiny market capitalisation and near-zero institutional following in the US market.

• Large single-session moves without news catalysts are characteristic of the stock's trading profile.

• Regencell is developing RGC-COG, a proprietary Traditional Chinese Medicine formulation for ADHD and autism spectrum disorder.

Regencell Bioscience (NASDAQ:RGC), a Hong Kong-based company developing Traditional Chinese Medicine-based treatments for ADHD and autism spectrum disorder using its proprietary RGC-COG formulation, closed at $8.56 on June 24, down nearly 23%, in a session that produced no company-specific announcement and is characteristic of the extreme single-session volatility associated with its micro-cap trading profile.

The company carries a tiny market capitalisation and near-zero institutional following in the US market, a profile in which large percentage moves without news catalysts are structurally expected rather than exceptional. With minimal float and no institutional market makers providing consistent two-way liquidity, the stock's price is subject to the mechanical dynamics of supply and demand imbalances among retail participants.

Regencell's RGC-COG formulation draws on Traditional Chinese Medicine ingredients in a proprietary blend that the company is advancing toward clinical validation for neurodevelopmental conditions. ADHD and autism spectrum disorder represent large and underserved therapeutic markets where interest in complementary and integrative treatment approaches has grown alongside dissatisfaction with existing pharmaceutical options.

The June 24 decline is consistent with the stock's established pattern and provides no new information about RGC-COG's development trajectory or regulatory pathway.